Page 1320 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

References 5

thrombotic microangiopathy in ADAMTS13-deficient mice. gene (CFB) and atypical hemolytic uremic syndrome. Pediatr
Blood. 2010;116(18):3653-3659. Nephrol. 2010;25(5):947-951.
127. Huang J, Haberichter SL, Sadler JE. The B subunits of Shiga- 143. Roumenina LT, Frimat M, Miller EC, et al. A prevalent C3
like toxins induce regulated VWF secretion in a phospholipase mutation in aHUS patients causes a direct C3 convertase gain
D1-dependent manner. Blood. 2012;120(5):1143-1149. of function. Blood. 2012;119(18):4182-4191.
128. Guessous F, Marcinkiewicz M, Polanowska-Grabowska R, et al. 144. Sartz L, Olin AI, Kristoffersson AC, et al. A novel C3 muta-
Shiga toxin 2 and lipopolysaccharide induce human microvas- tion causing increased formation of the C3 convertase in
cular endothelial cells to release chemokines and factors that familial atypical hemolytic uremic syndrome. J Immunol.
stimulate platelet function. Infect Immun. 2005;73(12):8306- 2012;188(4):2030-2037.
8316. 145. Lhotta K, Janecke AR, Scheiring J, et al. A large family with
129. Nestoridi E, Tsukurov O, Kushak RI, Ingelfinger JR, Grabowski a gain-of-function mutation of complement C3 predispos-
EF. Shiga toxin enhances functional tissue factor on human ing to atypical hemolytic uremic syndrome, microhematuria,
glomerular endothelial cells: implications for the pathophysi- hypertension and chronic renal failure. Clin J Am Soc Nephrol.
ology of hemolytic uremic syndrome. J Thromb Haemost. 2009;4(8):1356-1362.
2005;3(4):752-762. 146. Hogg PJ, Ohlin AK, Stenflo J. Identification of structural
130. Nestoridi E, Kushak RI, Duguerre D, Grabowski EF, Ingelfinger domains in protein C involved in its interaction with thrombin-
JR. Up-regulation of tissue factor activity on human proximal thrombomodulin on the surface of endothelial cells. J Biol
tubular epithelial cells in response to Shiga toxin. Kidney Int. Chem. 1992;267(2):703-706.
2005;67(6):2254-2266. 147. Rezaie AR, Esmon NL, Esmon CT. The high affinity calcium-
131. Stahl AL, Sartz L, Nelsson A, Bekassy ZD, Karpman D. Shiga binding site involved in protein C activation is outside the
toxin and lipopolysaccharide induce platelet-leukocyte aggre- first epidermal growth factor homology domain. J Biol Chem.
gates and tissue factor release, a thrombotic mechanism in 1992;267(17):11701-11704.
hemolytic uremic syndrome. PLoS One. 2009;4(9):e6990. 148. Edano T, Komine N, Yoshizaki H, Ohkuchi M. Protein C activa-
132. Fernandez GC, Te Loo MW, van der Velden TJ, van der Heuvel tion by recombinant thrombomodulin in plasma. Biol Pharm
LP, Palermo MS, Monnens LL. Decrease of thrombomodulin Bull. 1998;21(2):177-179.
contributes to the procoagulant state of endothelium in hemo- 149. Esmon CT. Protein C pathway in sepsis. Ann Med. 2002;34
lytic uremic syndrome. Pediatr Nephrol. 2003;18(10):1066-1068. (7-8):598-605.
133. Buddles MR, Donne RL, Richards A, Goodship J, Goodship 150. Kokame K, Zheng X, Sadler JE. Activation of thrombin-activable
TH. Complement factor H gene mutation associated with auto- fibrinolysis inhibitor requires epidermal growth factor-like
somal recessive atypical hemolytic uremic syndrome. Am J Hum domain 3 of thrombomodulin and is inhibited competitively by
Genet. 2000;66(5):1721-1722. protein C. J Biol Chem. 1998;273(20):12135-12139.
134. Zipfel PF. Complement factor H: physiology and pathophysiol- 151. Delvaeye M, Noris M, De VA, et al. Thrombomodulin muta-
ogy. Semin Thromb Hemost. 2001;27(3):191-199. tions in atypical hemolytic-uremic syndrome. N Engl J Med.
135. Neumann HP, Salzmann M, Bohnert-Iwan B, et al. Haemolytic 2009;361(4):345-357.
uraemic syndrome and mutations of the factor H gene: a reg- 152. Kavanagh D, Goodship TH. Atypical hemolytic uremic syn-
istry-based study of German speaking countries. J Med Genet. drome, genetic basis, and clinical manifestations. Hematology
2003;40(9):676-681. Am Soc Hematol Educ Program. 2011;2011:15-20.
136. Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJ. 153. George JN, Chen Q, Deford CC, Al-Nouri Z. Ten patient
Mutations in alternative pathway complement proteins in stories illustrating the extraordinarily diverse clinical
American patients with atypical hemolytic uremic syndrome. features of patients with thrombotic thrombocytopenic purpura
Hum Mutat. 2010;31(6):E1445-E1460. and severe ADAMTS13 deficiency. J Clin Apher. 2012;27(6):
137. Kopp A, Strobel S, Tortajada A, et al. Atypical hemolytic uremic 302-311.
syndrome-associated variants and autoantibodies impair bind- 154. Kinoshita S, Yoshioka A, Park YD, et al. Upshaw-Schulman
ing of factor h and factor h-related protein 1 to pentraxin 3. syndrome revisited: a concept of congenital thrombotic throm-
J Immunol. 2012;189(4):1858-1867. bocytopenic purpura. Int J Hematol. 2001;74(1):101-108.
138. Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: the impact 155. Siegler RL. The hemolytic uremic syndrome. Pediatr Clin North
of MCP, CFH, and IF mutations on clinical presentation, response Am. 1995;42(6):1505-1529.
to treatment, and outcome. Blood. 2006;108(4):1267-1279. 156. Garg AX, Suri RS, Barrowman N, et al. Long-term renal prog-
139. Zipfel PF, Skerka C. Complement dysfunction in hemolytic nosis of diarrhea-associated hemolytic uremic syndrome: a
uremic syndrome. Curr Opin Rheumatol. 2006;18(5):548-555. systematic review, meta-analysis, and meta-regression. JAMA.
140. Richards A, Kathryn LM, Kavanagh D et al. Implications of the 2003;290(10):1360-1370.
initial mutations in membrane cofactor protein (MCP; CD46) 157. Veyradier A, Obert B, Haddad E, et al. Severe deficiency of the
leading to atypical hemolytic uremic syndrome. Mol Immunol. specific von Willebrand factor-cleaving protease (ADAMTS
2007;44(1-3):111-122. 13) activity in a subgroup of children with atypical hemolytic
141. Geerdink LM, Westra D, van Wijk JA, et al. Atypical hemolytic uremic syndrome. J Pediatr. 2003;142(3):310-317.
uremic syndrome in children: complement mutations and clini- 158. Zheng XL. ADAMTS13 testing: why bother? Blood.
cal characteristics. Pediatr Nephrol. 2012;27(8):1283-1291. 2010;115(8):1475-1476.
142. Tawadrous H, Maga T, Sharma J, Kupferman J, Smith RJ, 159. Furlan M, Robles R, Galbusera M, et al. von Willebrand
Schoeneman M. A novel mutation in the complement factor B factor-cleaving protease in thrombotic thrombocytopenic

Section07-O-ref.indd 5 1/21/2015 11:26:49 AM